News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

1 rich Libsyn https://www.libsyn.com 90 600 News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia News from ASH 2020: No benefit from tranexamic acid prophylaxis in blood cancers: https://bit.ly/2K3Mah1 ‘Practice changing’: Ruxolitinib as second-line in chronic GVHD: https://bit.ly/3gT4kyg&nbsp; Durable responses with anti-BCMA CAR T-cell for multiple myeloma: https://bit.ly/381f1ut Five-minute SC injection of daratumumab in RRMM: https://bit.ly/3gKuZgx Email Blood &amp; Cancer at podcasts@mdedge.com &nbsp; Blood & Cancer https://www.mdedge.com/podcasts/blood-cancer <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/17186720/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/984545/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/item/17186720